Talphera, Inc. (TLPH)
USD 0.53
(4.55%)
USD 0.53
(4.55%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -18.39 Million USD | -138.52% |
| 2022 | 47.75 Million USD | 236.06% |
| 2021 | -35.09 Million USD | 13.08% |
| 2020 | -40.37 Million USD | 24.16% |
| 2019 | -53.24 Million USD | -12.92% |
| 2018 | -47.14 Million USD | 8.46% |
| 2017 | -51.5 Million USD | -19.35% |
| 2016 | -43.15 Million USD | -76.88% |
| 2015 | -24.39 Million USD | 26.85% |
| 2014 | -33.35 Million USD | -42.38% |
| 2013 | -23.42 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.95 Million USD | 12.46% |
| 2024 Q2 | -3.82 Million USD | 3.21% |
| 2023 Q2 | -4.37 Million USD | 46.38% |
| 2023 Q1 | -8.15 Million USD | -8.93% |
| 2023 Q3 | -1.35 Million USD | 68.95% |
| 2023 Q4 | -4.51 Million USD | -232.87% |
| 2023 FY | -18.39 Million USD | -138.52% |
| 2022 Q2 | 70.66 Million USD | 914.65% |
| 2022 Q1 | -8.67 Million USD | -9.56% |
| 2022 FY | 47.75 Million USD | 236.06% |
| 2022 Q4 | -7.48 Million USD | -10.87% |
| 2022 Q3 | -6.75 Million USD | -109.55% |
| 2021 Q2 | -9.85 Million USD | -9.99% |
| 2021 Q1 | -8.95 Million USD | -0.43% |
| 2021 FY | -35.09 Million USD | 13.08% |
| 2021 Q4 | -7.91 Million USD | 5.47% |
| 2021 Q3 | -8.37 Million USD | 14.98% |
| 2020 Q1 | -15.92 Million USD | -10.41% |
| 2020 FY | -40.37 Million USD | 24.16% |
| 2020 Q4 | -8.91 Million USD | 0.13% |
| 2020 Q3 | -8.93 Million USD | -35.18% |
| 2020 Q2 | -6.6 Million USD | 58.52% |
| 2019 Q1 | -13.67 Million USD | -8.89% |
| 2019 Q2 | -12.41 Million USD | 9.23% |
| 2019 FY | -53.24 Million USD | -12.92% |
| 2019 Q3 | -12.73 Million USD | -2.57% |
| 2019 Q4 | -14.42 Million USD | -13.29% |
| 2018 Q4 | -12.55 Million USD | -0.8% |
| 2018 Q1 | -11.59 Million USD | -17.27% |
| 2018 Q2 | -10.54 Million USD | 9.07% |
| 2018 FY | -47.14 Million USD | 8.46% |
| 2018 Q3 | -12.45 Million USD | -18.19% |
| 2017 Q1 | -15.55 Million USD | -60.62% |
| 2017 Q3 | -13.01 Million USD | 0.35% |
| 2017 Q4 | -9.88 Million USD | 24.04% |
| 2017 Q2 | -13.05 Million USD | 16.02% |
| 2017 FY | -51.5 Million USD | -19.35% |
| 2016 Q2 | -11.09 Million USD | -1.01% |
| 2016 Q4 | -9.68 Million USD | 15.09% |
| 2016 Q3 | -11.4 Million USD | -2.79% |
| 2016 Q1 | -10.98 Million USD | -4.12% |
| 2016 FY | -43.15 Million USD | -76.88% |
| 2015 FY | -24.39 Million USD | 26.85% |
| 2015 Q1 | -10.02 Million USD | 27.44% |
| 2015 Q4 | -10.54 Million USD | -308.05% |
| 2015 Q2 | -8.89 Million USD | 11.27% |
| 2015 Q3 | 5.06 Million USD | 156.98% |
| 2014 Q3 | 671 Thousand USD | 106.35% |
| 2014 Q4 | -13.81 Million USD | -2159.31% |
| 2014 Q2 | -10.57 Million USD | -9.8% |
| 2014 FY | -33.35 Million USD | -42.38% |
| 2014 Q1 | -9.63 Million USD | -154.2% |
| 2013 FY | -23.42 Million USD | 0.0% |
| 2013 Q1 | -12.76 Million USD | 0.0% |
| 2013 Q2 | -17.44 Million USD | -36.71% |
| 2013 Q3 | -10.98 Million USD | 37.03% |
| 2013 Q4 | 17.76 Million USD | 261.74% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 91.208% |
| Theratechnologies Inc. | -23.95 Million USD | 23.208% |
| Safety Shot Inc | -15.08 Million USD | -21.971% |
| Cosmos Health Inc. | -18.54 Million USD | 0.786% |
| Cronos Group Inc. | -73.96 Million USD | 75.127% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 98.164% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 56.404% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 472.032% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -198.504% |
| ProPhase Labs, Inc. | -16.78 Million USD | -9.623% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -280.496% |
| Dynavax Technologies Corporation | -6.38 Million USD | -187.948% |
| Radius Health, Inc. | -25.79 Million USD | 28.669% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -493.733% |
| Alvotech | -551.73 Million USD | 96.666% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -308.274% |
| Alpha Teknova, Inc. | -36.78 Million USD | 49.981% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 86.829% |
| SCYNEXIS, Inc. | 67.04 Million USD | 127.441% |
| Harrow Health, Inc. | -24.41 Million USD | 24.636% |
| Biofrontera Inc. | -20.13 Million USD | 8.614% |
| DURECT Corporation | -27.62 Million USD | 33.402% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1497.948% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 197.966% |
| OptiNose, Inc. | -35.48 Million USD | 48.153% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 176.923% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -133.761% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -192.978% |
| SIGA Technologies, Inc. | 68.06 Million USD | 127.027% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 253.142% |
| Shineco, Inc. | -22.44 Million USD | 18.05% |
| Phibro Animal Health Corporation | 2.41 Million USD | 861.465% |
| Procaps Group S.A. | 42.54 Million USD | 143.246% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -78.994% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -327.655% |
| Viatris Inc. | 54.7 Million USD | 133.633% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -308.274% |
| Rockwell Medical, Inc. | -8.43 Million USD | -118.0% |
| Incannex Healthcare Limited | -18.45 Million USD | 0.336% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -16.113% |
| Tilray Brands, Inc. | -244.98 Million USD | 92.49% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 138.204% |
| PetIQ, Inc. | 2.13 Million USD | 963.304% |
| Silver Spike Investment Corp. | 7.34 Million USD | 350.637% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 107.368% |
| Journey Medical Corporation | -3.85 Million USD | -377.472% |
| Alimera Sciences, Inc. | -20.13 Million USD | 8.618% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -125.365% |
| Assertio Holdings, Inc. | -331.94 Million USD | 94.458% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -179.05% |
| Embecta Corp. | 70.4 Million USD | 126.132% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 8.278% |
| Procaps Group, S.A. | 42.54 Million USD | 143.246% |
| PainReform Ltd. | -9.34 Million USD | -96.886% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 88.522% |
| Hempacco Co., Inc. | -13.12 Million USD | -40.156% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 143.849% |
| Alvotech | -551.73 Million USD | 96.666% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 105.632% |
| Kamada Ltd. | 8.28 Million USD | 322.079% |
| Indivior PLC | 2 Million USD | 1019.85% |
| Currenc Group, Inc. | -15.3 Million USD | -20.19% |
| Evoke Pharma, Inc. | -7.79 Million USD | -136.092% |
| Flora Growth Corp. | -57.03 Million USD | 67.745% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 8.278% |
| Evolus, Inc. | -61.68 Million USD | 70.176% |
| HUTCHMED (China) Limited | 100.78 Million USD | 118.255% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 113.375% |
| Akanda Corp. | -32.27 Million USD | 42.999% |